SER-109 is an investigational microbiome therapeutic made of purified Firmicutes spores.
The study was a phase 3 double-blind, randomized, placebo-controlled trial. The participants all had three or more C. difficile episodes and received SER-109 or a placebo. Of the 182 participants in the study, 12 percent of those who received SER-109 had recurring C. difficile after the treatment compared with 40 percent in the placebo group.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
